Everything tagged "vaccines" across the TickerSpark archives.
Moderna is a high-risk transition story as COVID revenue fades, but a strong Phase 3 melanoma result and a larger cash cushion keep the long-term thesis alive. The stock looks like a Hold while investors wait to see whether respiratory vaccines and oncology can drive durable earnings.
Moderna’s latest drop looks more like regulatory panic than a broken thesis. With an Aug. 5 FDA decision now in sight and the flu program still under active review, the selloff looks overdone.
Sanofi is becoming a more focused biopharma compounder, led by Dupixent growth, vaccine strength, and expanding launch sales. The stock looks inexpensive versus its cash generation and earnings power.
GSK is evolving from a mature pharma cash generator into a more balanced growth story, with Specialty Medicines driving faster growth and margins improving. The stock still looks reasonably valued versus its earnings power and pipeline.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the GeneratorCancel anytime